文献速递药物相互作用特殊人群用药治疗药物监测与药物基因组学

比克替拉韦/恩曲他滨/丙酚替诺福韦与女性化激素治疗的药物相互作用研究方案

Protocol of a drug-drug interaction study between bictegravir/emtricitabine/tenofovir alafenamide and feminizing hormones in trans women living with HIV.
PubMed 文献 · Br J Clin Pharmacol · 2024-07-11

本研究方案针对跨性别女性HIV感染者,探讨女性化激素治疗(口服雌二醇和抗雄药物)与B/F/TAF抗逆转录病毒方案的双向药代动力学相互作用。采用三臂平行纵向6个月设计,比较HIV感染跨性别女性、HIV感染顺性别女性及未感染HIV跨性别女性的药物浓度,主要结局为B/F/TAF和雌二醇的药代参数。

要点

  • B/F/TAF与女性化激素治疗可能存在双向药代相互作用,需评估。
  • 研究比较三组人群的药代参数,包括HIV感染与未感染的跨性别女性。
  • 主要结局为B/F/TAF的Cmin、Cmax、AUC及雌二醇的Cmin、C4h、Cmax、AUC。

核心结论

  • 本研究旨在提供B/F/TAF与女性化激素治疗安全联用的关键药代动力学信息。

研究设计与样本

  • 三臂平行纵向6个月药物相互作用研究方案,每组15人。
  • 组1为15名接受FHT和ART的HIV感染跨性别女性;组2为15名接受ART的HIV感染绝经前顺性别女性;组3为15名接受FHT的未感染HIV跨性别女性。
  • HIV感染者基线时须正在使用或换用B/F/TAF且病毒抑制≥3个月。
  • 跨性别女性须稳定使用≥2 mg/日口服雌二醇及抗雄药物≥3个月。

关键数值与推荐

  • 主要结局为第2个月B/F/TAF的药代参数(Cmin、Cmax、AUC)和雌二醇浓度(Cmin、C4h、Cmax、AUC)。
  • 血浆ART药物浓度在第2个月采样,组1与组2比较。
  • 血清雌二醇浓度在基线和第2个月采样,组1与组3比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Trans/transfeminine women are disproportionally affected by HIV. Concerns regarding negative drug-drug interactions (DDIs) between ART drugs and gender-affirming hormone therapy (GAHT), specifically feminizing hormone therapy (FHT), may contribute to the lower ART uptake by trans women with HIV compared with their cis counterparts. The aim of this study is to investigate the bidirectional pharmacokinetic effects of components of FHT regimens (oral oestradiol and androgen-suppressing medications) with the ART regimen (bictegravir/emtricitabine/tenofovir alafenamide [B/F/TAF)]. METHODS: We present a protocol for a three-armed, parallel-group, longitudinal (6-month), DDI study. Group 1 includes 15 3trans women with HIV taking FHT and ART; group 2 includes 15 premenopausal cis women with HIV taking ART; group 3 includes 15 trans women without HIV taking FHT. Women with HIV must be on or switch to B/F/TAF at baseline and be virally suppressed for ≥3 months. Trans women must be taking a stable regimen of ≥2 mg daily oral oestradiol and an anti-androgen (pharmaceutical, and/or surgical, and/or medical) for ≥3 months. Plasma ART drug concentrations will be sampled at Month 2 and compared between groups 1 and 2. Serum oestradiol concentrations will be sampled at baseline and Month 2 visits and compared between groups 1 and 3. The primary outcomes are B/F/TAF pharmacokinetic parameters (Cmin, Cmax and AUC) and oestradiol concentrations (Cmin, C4h, Cmax and AUC) at month 2. DISCUSSION: This study is of global importance as it provides critical information regarding safe coadministration of B/F/TAF and FHT, both of which are life-saving therapies for trans women with HIV.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Lacombe-Duncan A, Tseng A, Scarsi KK, et al. Protocol of a drug-drug interaction study between bictegravir/emtricitabine/tenofovir alafenamide and feminizing hormones in trans women living with HIV. Br J Clin Pharmacol. 2024. PMID: 38992893. doi:10.1111/bcp.16162

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。